Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative immunotherapy solutions aimed at addressing significant unmet medical needs in autoimmune and rare diseases. The company employs proprietary technology platforms to build a robust pipeline of therapies that enhance immune responses and improve patient outcomes. With a strong focus on commercialization and advancing its unique therapies, Zenas is strategically positioning itself as a key player in the biopharmaceutical sector, committed to transforming treatment paradigms for complex health conditions. Show more

Location: 852 WINTER STREET, WALTHAM, MA, UNITED STATES, 02451, Waltham, MA, 02451, USA | Website: https://zenasbio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.914B

52 Wk Range

$6.11 - $44.60

Previous Close

$18.37

Open

$18.33

Volume

854,918

Day Range

$17.60 - $18.72

Enterprise Value

696M

Cash

115.6M

Avg Qtr Burn

-41.13M

Insider Ownership

26.50%

Institutional Own.

64.67%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Obexelimab (CD19xFcyRIIb) Details IgG4-related disease	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Orelabrutinib (BTK Inhibitor) Details Primary Progressive Multiple Sclerosis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Orelabrutinib (BTK Inhibitor) Details Secondary Progressive Multiple Sclerosis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19xFcyRIIb) Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19xFcyRIIb) Details Multiple sclerosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Orelabrutinib (BTK Inhibitor) Details Systemic Lupus Erythematosus	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19xFcyRIIb) Details Warm autoimmune hemolytic anemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.